Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myocardium | 24 | 2019 | 529 | 2.860 |
Why?
|
Heart-Assist Devices | 14 | 2016 | 731 | 2.540 |
Why?
|
Receptors, Adrenergic, beta | 15 | 2018 | 72 | 2.410 |
Why?
|
Platelet Aggregation Inhibitors | 3 | 2022 | 134 | 1.690 |
Why?
|
Heart Failure | 19 | 2019 | 1204 | 1.630 |
Why?
|
G-Protein-Coupled Receptor Kinase 2 | 7 | 2015 | 22 | 1.510 |
Why?
|
Ventricular Remodeling | 4 | 2019 | 96 | 1.350 |
Why?
|
Coronary Artery Bypass | 6 | 2022 | 228 | 1.310 |
Why?
|
Polyethylene Glycols | 3 | 2018 | 363 | 1.300 |
Why?
|
Heart | 9 | 2011 | 539 | 1.210 |
Why?
|
Arrestins | 3 | 2015 | 8 | 1.190 |
Why?
|
Heart Transplantation | 10 | 2016 | 705 | 1.110 |
Why?
|
Platelet Function Tests | 2 | 2022 | 11 | 1.090 |
Why?
|
Signal Transduction | 16 | 2019 | 3241 | 1.060 |
Why?
|
Brain Death | 7 | 2014 | 69 | 0.960 |
Why?
|
Oxidative Stress | 3 | 2015 | 447 | 0.950 |
Why?
|
Myocardial Reperfusion Injury | 4 | 2014 | 57 | 0.930 |
Why?
|
Patient Readmission | 4 | 2016 | 329 | 0.890 |
Why?
|
Fibroblasts | 6 | 2019 | 729 | 0.840 |
Why?
|
Heart Ventricles | 8 | 2011 | 760 | 0.830 |
Why?
|
Myocytes, Cardiac | 6 | 2019 | 275 | 0.810 |
Why?
|
Thrombelastography | 1 | 2021 | 47 | 0.800 |
Why?
|
Apoptosis | 5 | 2018 | 1683 | 0.770 |
Why?
|
beta-Adrenergic Receptor Kinases | 9 | 2006 | 12 | 0.730 |
Why?
|
Ventricular Function | 2 | 2011 | 53 | 0.710 |
Why?
|
Myofibroblasts | 3 | 2019 | 43 | 0.660 |
Why?
|
NADPH Oxidases | 2 | 2015 | 81 | 0.650 |
Why?
|
Prosthesis-Related Infections | 2 | 2015 | 58 | 0.640 |
Why?
|
Prosthesis Implantation | 2 | 2015 | 125 | 0.600 |
Why?
|
Tricuspid Valve | 2 | 2014 | 96 | 0.560 |
Why?
|
Myocardial Infarction | 2 | 2019 | 376 | 0.550 |
Why?
|
Mitochondria | 2 | 2015 | 535 | 0.520 |
Why?
|
Fibrillar Collagens | 1 | 2014 | 10 | 0.510 |
Why?
|
Cardiac Valve Annuloplasty | 1 | 2014 | 13 | 0.490 |
Why?
|
Rats | 10 | 2019 | 3990 | 0.480 |
Why?
|
Hemorrhage | 1 | 2016 | 268 | 0.480 |
Why?
|
Myocardial Contraction | 14 | 2014 | 244 | 0.480 |
Why?
|
Collagen | 2 | 2015 | 269 | 0.470 |
Why?
|
Caspase 3 | 4 | 2018 | 159 | 0.470 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 8 | 2000 | 107 | 0.470 |
Why?
|
Receptors, Adrenergic, beta-2 | 5 | 2008 | 36 | 0.470 |
Why?
|
Recovery of Function | 5 | 2017 | 272 | 0.470 |
Why?
|
Length of Stay | 5 | 2017 | 702 | 0.460 |
Why?
|
Male | 43 | 2019 | 40965 | 0.460 |
Why?
|
Ventricular Function, Left | 7 | 2018 | 592 | 0.460 |
Why?
|
Postoperative Complications | 9 | 2017 | 2207 | 0.460 |
Why?
|
Snoring | 1 | 2013 | 12 | 0.450 |
Why?
|
Heart Arrest, Induced | 3 | 2017 | 31 | 0.450 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2012 | 44 | 0.440 |
Why?
|
Saphenous Vein | 1 | 2012 | 61 | 0.440 |
Why?
|
Organ Preservation Solutions | 2 | 2014 | 28 | 0.440 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2012 | 78 | 0.440 |
Why?
|
Humans | 54 | 2022 | 86643 | 0.430 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2014 | 111 | 0.430 |
Why?
|
Protein Kinase C-alpha | 2 | 2010 | 27 | 0.410 |
Why?
|
Propanolamines | 3 | 2008 | 36 | 0.410 |
Why?
|
beta-Arrestins | 3 | 2015 | 8 | 0.400 |
Why?
|
Pericardium | 1 | 2011 | 65 | 0.390 |
Why?
|
Cardiopulmonary Bypass | 3 | 2017 | 148 | 0.380 |
Why?
|
Adrenergic beta-Antagonists | 3 | 2008 | 152 | 0.380 |
Why?
|
Phosphorylation | 6 | 2020 | 1106 | 0.380 |
Why?
|
GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2010 | 7 | 0.370 |
Why?
|
Cardiotonic Agents | 3 | 2012 | 87 | 0.370 |
Why?
|
Middle Aged | 29 | 2018 | 25028 | 0.370 |
Why?
|
Animals | 34 | 2019 | 26582 | 0.370 |
Why?
|
Janus Kinase 2 | 1 | 2010 | 57 | 0.360 |
Why?
|
STAT3 Transcription Factor | 1 | 2010 | 78 | 0.360 |
Why?
|
Membrane Glycoproteins | 4 | 2015 | 428 | 0.360 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2013 | 219 | 0.360 |
Why?
|
Coronary Vessels | 1 | 2011 | 177 | 0.350 |
Why?
|
Sodium-Hydrogen Exchangers | 4 | 2002 | 79 | 0.350 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2017 | 318 | 0.350 |
Why?
|
GTP-Binding Proteins | 6 | 2006 | 146 | 0.340 |
Why?
|
Treatment Outcome | 14 | 2022 | 7993 | 0.330 |
Why?
|
Female | 33 | 2018 | 44532 | 0.330 |
Why?
|
Cells, Cultured | 6 | 2015 | 2818 | 0.330 |
Why?
|
Smoking | 1 | 2012 | 609 | 0.330 |
Why?
|
Catheterization | 1 | 2010 | 232 | 0.330 |
Why?
|
Nitric Oxide | 1 | 2010 | 278 | 0.330 |
Why?
|
Organ Preservation | 2 | 2008 | 83 | 0.320 |
Why?
|
Postoperative Care | 3 | 2016 | 221 | 0.320 |
Why?
|
RNA, Messenger | 3 | 2012 | 1981 | 0.320 |
Why?
|
Aortic Aneurysm, Thoracic | 2 | 2021 | 87 | 0.320 |
Why?
|
Stress, Physiological | 1 | 2010 | 227 | 0.320 |
Why?
|
Time Factors | 12 | 2017 | 5210 | 0.320 |
Why?
|
Incidence | 7 | 2016 | 1577 | 0.320 |
Why?
|
Cyclic AMP | 5 | 2015 | 273 | 0.310 |
Why?
|
Retrospective Studies | 17 | 2021 | 8489 | 0.300 |
Why?
|
Intraoperative Complications | 1 | 2008 | 185 | 0.300 |
Why?
|
Rats, Sprague-Dawley | 4 | 2019 | 1219 | 0.290 |
Why?
|
Gene Expression Regulation | 3 | 2012 | 1920 | 0.290 |
Why?
|
Molecular Weight | 2 | 2018 | 332 | 0.290 |
Why?
|
Receptors, Adrenergic, beta-1 | 1 | 2006 | 8 | 0.280 |
Why?
|
Mice, Transgenic | 13 | 2010 | 1540 | 0.280 |
Why?
|
Cardiac Surgical Procedures | 3 | 2017 | 462 | 0.280 |
Why?
|
Isoproterenol | 5 | 2015 | 59 | 0.270 |
Why?
|
Oxygen | 1 | 2011 | 726 | 0.270 |
Why?
|
NADPH Oxidase 4 | 2 | 2015 | 15 | 0.270 |
Why?
|
Survival Rate | 6 | 2017 | 1863 | 0.270 |
Why?
|
Transforming Growth Factor beta | 3 | 2019 | 301 | 0.260 |
Why?
|
Adult | 20 | 2021 | 25648 | 0.260 |
Why?
|
Histiocytoma, Benign Fibrous | 1 | 2004 | 25 | 0.260 |
Why?
|
Reperfusion Injury | 1 | 2006 | 131 | 0.260 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 2 | 2015 | 115 | 0.250 |
Why?
|
Heart Neoplasms | 1 | 2004 | 62 | 0.250 |
Why?
|
MAP Kinase Signaling System | 2 | 2014 | 192 | 0.240 |
Why?
|
Follow-Up Studies | 7 | 2017 | 3640 | 0.230 |
Why?
|
Atrial Fibrillation | 3 | 2018 | 288 | 0.230 |
Why?
|
Gene Transfer Techniques | 3 | 1999 | 152 | 0.230 |
Why?
|
Coronary Artery Disease | 2 | 2018 | 350 | 0.230 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2022 | 5 | 0.220 |
Why?
|
Aortic Valve | 2 | 2016 | 222 | 0.210 |
Why?
|
Kidney Tubules, Proximal | 1 | 2002 | 61 | 0.210 |
Why?
|
Receptors, Adrenergic, alpha | 2 | 1999 | 16 | 0.210 |
Why?
|
Perfusion | 3 | 2014 | 203 | 0.210 |
Why?
|
Catecholamines | 2 | 2020 | 88 | 0.210 |
Why?
|
Aging | 1 | 2006 | 691 | 0.200 |
Why?
|
Blood Platelets | 1 | 2021 | 149 | 0.200 |
Why?
|
Aged | 18 | 2017 | 18415 | 0.190 |
Why?
|
Reactive Oxygen Species | 2 | 2015 | 480 | 0.190 |
Why?
|
Mitochondria, Heart | 1 | 2020 | 50 | 0.190 |
Why?
|
Adrenergic beta-Agonists | 3 | 2015 | 72 | 0.190 |
Why?
|
Peptide Fragments | 2 | 1999 | 460 | 0.190 |
Why?
|
Tissue Donors | 3 | 2014 | 463 | 0.190 |
Why?
|
Swine | 5 | 2008 | 555 | 0.180 |
Why?
|
beta-Arrestin 2 | 1 | 2019 | 3 | 0.180 |
Why?
|
beta-Arrestin 1 | 1 | 2019 | 4 | 0.180 |
Why?
|
Disease Models, Animal | 7 | 2019 | 2232 | 0.180 |
Why?
|
Mitral Valve | 2 | 2012 | 248 | 0.180 |
Why?
|
Mice | 14 | 2010 | 11352 | 0.170 |
Why?
|
Angiotensin II | 2 | 2015 | 94 | 0.170 |
Why?
|
Tomography, X-Ray Computed | 3 | 2017 | 2601 | 0.170 |
Why?
|
Caveolin 1 | 1 | 2018 | 20 | 0.170 |
Why?
|
Acute Kidney Injury | 2 | 2014 | 295 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2004 | 1313 | 0.160 |
Why?
|
Sensitivity and Specificity | 4 | 2013 | 1991 | 0.160 |
Why?
|
Nitrates | 1 | 2018 | 35 | 0.160 |
Why?
|
Cardiovascular Agents | 1 | 2018 | 56 | 0.160 |
Why?
|
Risk Factors | 9 | 2021 | 5417 | 0.160 |
Why?
|
Receptors, Adrenergic, alpha-1 | 1 | 1997 | 7 | 0.160 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 1998 | 73 | 0.160 |
Why?
|
Cell Line | 4 | 2015 | 2468 | 0.150 |
Why?
|
Recombinant Proteins | 1 | 1999 | 1014 | 0.150 |
Why?
|
Interleukin-6 | 2 | 2010 | 256 | 0.150 |
Why?
|
Genetic Predisposition to Disease | 1 | 2006 | 2271 | 0.150 |
Why?
|
Rhodopsin | 2 | 2015 | 19 | 0.150 |
Why?
|
Aortic Diseases | 1 | 2017 | 100 | 0.150 |
Why?
|
Amiodarone | 1 | 2016 | 12 | 0.150 |
Why?
|
Protein Processing, Post-Translational | 1 | 1999 | 371 | 0.150 |
Why?
|
Imaging, Three-Dimensional | 2 | 2017 | 579 | 0.150 |
Why?
|
Aorta, Thoracic | 1 | 2017 | 165 | 0.140 |
Why?
|
Aortic Aneurysm | 1 | 2017 | 80 | 0.140 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2016 | 58 | 0.140 |
Why?
|
Calcium Channels, L-Type | 3 | 2005 | 39 | 0.140 |
Why?
|
Creatinine | 2 | 2014 | 338 | 0.140 |
Why?
|
Pulsatile Flow | 1 | 2016 | 49 | 0.140 |
Why?
|
Microscopy, Confocal | 2 | 2015 | 268 | 0.140 |
Why?
|
NADPH Oxidase 2 | 1 | 2015 | 20 | 0.140 |
Why?
|
Cost-Benefit Analysis | 2 | 2016 | 454 | 0.140 |
Why?
|
Acetophenones | 1 | 2015 | 27 | 0.140 |
Why?
|
Pneumothorax | 1 | 2016 | 52 | 0.140 |
Why?
|
Ileus | 1 | 2015 | 9 | 0.130 |
Why?
|
Cell Line, Transformed | 1 | 2015 | 154 | 0.130 |
Why?
|
Superoxides | 1 | 2015 | 73 | 0.130 |
Why?
|
Equipment Failure | 1 | 2016 | 119 | 0.130 |
Why?
|
Heart Valve Diseases | 2 | 2016 | 109 | 0.130 |
Why?
|
Hospital Costs | 2 | 2016 | 105 | 0.130 |
Why?
|
Silicones | 1 | 2014 | 16 | 0.130 |
Why?
|
Area Under Curve | 2 | 2013 | 334 | 0.130 |
Why?
|
Gene Knockdown Techniques | 2 | 2019 | 236 | 0.130 |
Why?
|
Costs and Cost Analysis | 1 | 2015 | 153 | 0.130 |
Why?
|
Smad Proteins | 1 | 2014 | 39 | 0.130 |
Why?
|
Ambulatory Care | 1 | 2016 | 181 | 0.130 |
Why?
|
In Situ Nick-End Labeling | 1 | 2014 | 121 | 0.130 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2014 | 63 | 0.120 |
Why?
|
Global Health | 1 | 2016 | 193 | 0.120 |
Why?
|
RNA Interference | 1 | 2015 | 369 | 0.120 |
Why?
|
Intraoperative Period | 1 | 2014 | 90 | 0.120 |
Why?
|
Adenylyl Cyclases | 3 | 1999 | 100 | 0.120 |
Why?
|
Lung Transplantation | 1 | 2016 | 175 | 0.120 |
Why?
|
Organ Transplantation | 1 | 2017 | 265 | 0.120 |
Why?
|
Serum Albumin | 1 | 2014 | 130 | 0.120 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2014 | 58 | 0.120 |
Why?
|
Transgenes | 3 | 1999 | 180 | 0.120 |
Why?
|
Up-Regulation | 2 | 2015 | 712 | 0.120 |
Why?
|
RNA, Small Interfering | 1 | 2015 | 547 | 0.120 |
Why?
|
Glucocorticoids | 2 | 2007 | 352 | 0.120 |
Why?
|
Enzyme Activation | 2 | 2010 | 692 | 0.120 |
Why?
|
Tissue and Organ Harvesting | 1 | 2014 | 78 | 0.120 |
Why?
|
Pneumonectomy | 1 | 2016 | 196 | 0.120 |
Why?
|
Cell Survival | 2 | 2014 | 969 | 0.120 |
Why?
|
Mitral Valve Annuloplasty | 1 | 2013 | 16 | 0.120 |
Why?
|
Heart Atria | 2 | 2014 | 250 | 0.120 |
Why?
|
Hypertension, Pulmonary | 2 | 2012 | 346 | 0.120 |
Why?
|
ROC Curve | 2 | 2013 | 752 | 0.110 |
Why?
|
Biomarkers | 2 | 2010 | 1718 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2014 | 322 | 0.110 |
Why?
|
Sleep, REM | 1 | 2013 | 50 | 0.110 |
Why?
|
Bacterial Infections | 1 | 2014 | 182 | 0.110 |
Why?
|
Connexins | 1 | 2014 | 200 | 0.110 |
Why?
|
Sleep Stages | 1 | 2013 | 45 | 0.110 |
Why?
|
Raffinose | 2 | 2014 | 24 | 0.110 |
Why?
|
Xanthenes | 1 | 2012 | 23 | 0.110 |
Why?
|
Luminescent Proteins | 3 | 2002 | 144 | 0.110 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2016 | 275 | 0.110 |
Why?
|
Adenoviridae | 3 | 1999 | 345 | 0.110 |
Why?
|
Hypertrophy, Right Ventricular | 1 | 2012 | 33 | 0.110 |
Why?
|
Gene Expression | 6 | 2010 | 1284 | 0.110 |
Why?
|
Genetic Vectors | 3 | 1999 | 439 | 0.110 |
Why?
|
Receptors, Dopamine D1 | 1 | 2012 | 34 | 0.110 |
Why?
|
Glutathione | 2 | 2014 | 104 | 0.110 |
Why?
|
Allopurinol | 2 | 2014 | 80 | 0.110 |
Why?
|
Severity of Illness Index | 2 | 2017 | 1801 | 0.110 |
Why?
|
Recombinant Fusion Proteins | 4 | 2002 | 557 | 0.110 |
Why?
|
Down-Regulation | 2 | 2012 | 504 | 0.110 |
Why?
|
Logistic Models | 2 | 2013 | 1186 | 0.100 |
Why?
|
Arousal | 1 | 2013 | 170 | 0.100 |
Why?
|
Phenylephrine | 2 | 2004 | 35 | 0.100 |
Why?
|
Heart Diseases | 1 | 2014 | 290 | 0.100 |
Why?
|
Models, Animal | 2 | 2011 | 263 | 0.100 |
Why?
|
Preoperative Care | 2 | 2016 | 397 | 0.100 |
Why?
|
Skin | 1 | 2014 | 554 | 0.100 |
Why?
|
Mitral Valve Insufficiency | 1 | 2013 | 187 | 0.100 |
Why?
|
Mediastinum | 1 | 2011 | 46 | 0.100 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 1373 | 0.100 |
Why?
|
Registries | 1 | 2014 | 702 | 0.100 |
Why?
|
Membrane Microdomains | 1 | 2011 | 54 | 0.100 |
Why?
|
Immunoblotting | 2 | 2008 | 268 | 0.100 |
Why?
|
Probability | 2 | 2008 | 355 | 0.090 |
Why?
|
Transfection | 3 | 2002 | 896 | 0.090 |
Why?
|
Cohort Studies | 3 | 2016 | 2767 | 0.090 |
Why?
|
Cardiovascular Diseases | 1 | 2017 | 827 | 0.090 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 2010 | 21 | 0.090 |
Why?
|
Cell Hypoxia | 1 | 2011 | 164 | 0.090 |
Why?
|
Tropomyosin | 1 | 2010 | 15 | 0.090 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2010 | 86 | 0.090 |
Why?
|
Adenosine | 2 | 2014 | 225 | 0.090 |
Why?
|
Proto-Oncogene Proteins | 2 | 2010 | 645 | 0.090 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2010 | 97 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 860 | 0.090 |
Why?
|
Suture Techniques | 1 | 2010 | 135 | 0.090 |
Why?
|
Proportional Hazards Models | 3 | 2017 | 859 | 0.090 |
Why?
|
Membrane Proteins | 2 | 2010 | 1196 | 0.080 |
Why?
|
Echocardiography | 1 | 2014 | 911 | 0.080 |
Why?
|
Academic Medical Centers | 2 | 2021 | 379 | 0.080 |
Why?
|
Kidney Failure, Chronic | 1 | 2014 | 509 | 0.080 |
Why?
|
Cell Proliferation | 1 | 2014 | 1578 | 0.080 |
Why?
|
Diglycerides | 2 | 1998 | 22 | 0.080 |
Why?
|
Cardioplegic Solutions | 1 | 2008 | 17 | 0.080 |
Why?
|
Cell Differentiation | 1 | 2014 | 1458 | 0.080 |
Why?
|
Atrial Natriuretic Factor | 2 | 1998 | 39 | 0.080 |
Why?
|
Chronic Disease | 2 | 2010 | 971 | 0.080 |
Why?
|
Blood Vessel Prosthesis | 1 | 2010 | 228 | 0.080 |
Why?
|
In Vitro Techniques | 2 | 2008 | 989 | 0.080 |
Why?
|
Lymphocytes | 1 | 2010 | 464 | 0.080 |
Why?
|
Sodium-Hydrogen Exchanger 3 | 3 | 2002 | 32 | 0.080 |
Why?
|
Elective Surgical Procedures | 1 | 2008 | 116 | 0.080 |
Why?
|
Ventricular Function, Right | 2 | 2017 | 142 | 0.080 |
Why?
|
Insulin | 2 | 2014 | 1160 | 0.070 |
Why?
|
Coronary Disease | 1 | 2008 | 261 | 0.070 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2007 | 71 | 0.070 |
Why?
|
Immunocompromised Host | 2 | 2004 | 140 | 0.070 |
Why?
|
Multivariate Analysis | 3 | 2014 | 999 | 0.070 |
Why?
|
Ventricular Pressure | 2 | 2014 | 34 | 0.070 |
Why?
|
Analysis of Variance | 1 | 2008 | 912 | 0.070 |
Why?
|
Interleukin-10 | 1 | 2007 | 149 | 0.070 |
Why?
|
Methylprednisolone | 1 | 2005 | 66 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 1 | 2017 | 3362 | 0.070 |
Why?
|
Wisconsin | 2 | 2016 | 39 | 0.070 |
Why?
|
Mice, Knockout | 1 | 2010 | 1924 | 0.070 |
Why?
|
Viral Envelope Proteins | 2 | 2002 | 94 | 0.060 |
Why?
|
Caveolins | 1 | 2004 | 2 | 0.060 |
Why?
|
Mediastinitis | 1 | 2004 | 14 | 0.060 |
Why?
|
Strongyloidiasis | 1 | 2004 | 5 | 0.060 |
Why?
|
Adrenergic alpha-Agonists | 1 | 2004 | 34 | 0.060 |
Why?
|
Suction | 1 | 2004 | 35 | 0.060 |
Why?
|
Sternum | 1 | 2004 | 30 | 0.060 |
Why?
|
Therapeutic Irrigation | 1 | 2004 | 60 | 0.060 |
Why?
|
Algorithms | 1 | 2013 | 1830 | 0.060 |
Why?
|
Cell Membrane | 3 | 2002 | 666 | 0.060 |
Why?
|
Debridement | 1 | 2004 | 56 | 0.060 |
Why?
|
Cardiomegaly | 1 | 2004 | 111 | 0.060 |
Why?
|
Prosthesis Design | 2 | 2015 | 278 | 0.060 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2007 | 683 | 0.060 |
Why?
|
Protein Kinase C | 2 | 2004 | 270 | 0.060 |
Why?
|
Opossums | 1 | 2002 | 4 | 0.060 |
Why?
|
Intracellular Fluid | 1 | 2002 | 34 | 0.060 |
Why?
|
Microvilli | 1 | 2002 | 43 | 0.050 |
Why?
|
Cell Compartmentation | 1 | 2002 | 69 | 0.050 |
Why?
|
Surgical Wound Infection | 1 | 2004 | 184 | 0.050 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 268 | 0.050 |
Why?
|
Macromolecular Substances | 1 | 2002 | 177 | 0.050 |
Why?
|
Androstadienes | 1 | 2002 | 72 | 0.050 |
Why?
|
Endosomes | 1 | 2002 | 75 | 0.050 |
Why?
|
Actins | 2 | 2019 | 451 | 0.050 |
Why?
|
Drug Therapy, Combination | 1 | 2004 | 894 | 0.050 |
Why?
|
Fluorescent Antibody Technique | 1 | 2002 | 316 | 0.050 |
Why?
|
Patient Selection | 2 | 2016 | 685 | 0.050 |
Why?
|
Disease Progression | 2 | 2017 | 1531 | 0.050 |
Why?
|
Stroke Volume | 3 | 2017 | 456 | 0.050 |
Why?
|
Staphylococcal Infections | 1 | 2004 | 255 | 0.050 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2002 | 493 | 0.050 |
Why?
|
Virulence Factors, Bordetella | 2 | 1999 | 26 | 0.050 |
Why?
|
Pertussis Toxin | 2 | 1999 | 31 | 0.050 |
Why?
|
Aged, 80 and over | 3 | 2017 | 6509 | 0.050 |
Why?
|
Fluorescent Dyes | 1 | 2002 | 242 | 0.050 |
Why?
|
Aldehyde Dehydrogenase | 1 | 2020 | 14 | 0.050 |
Why?
|
Monoamine Oxidase | 1 | 2020 | 24 | 0.050 |
Why?
|
Protein Transport | 1 | 2002 | 411 | 0.050 |
Why?
|
Cardiac Output | 1 | 2001 | 156 | 0.050 |
Why?
|
CD8 Antigens | 1 | 2000 | 82 | 0.050 |
Why?
|
Rabbits | 2 | 2000 | 636 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2016 | 916 | 0.050 |
Why?
|
Cytoplasmic Vesicles | 1 | 2000 | 5 | 0.050 |
Why?
|
Feasibility Studies | 2 | 1999 | 751 | 0.050 |
Why?
|
Vidarabine | 1 | 2000 | 141 | 0.050 |
Why?
|
Viral Proteins | 1 | 2001 | 300 | 0.050 |
Why?
|
Sodium Fluoride | 1 | 1999 | 3 | 0.050 |
Why?
|
Oxidation-Reduction | 1 | 2020 | 373 | 0.040 |
Why?
|
Case-Control Studies | 2 | 2014 | 1805 | 0.040 |
Why?
|
Enzyme Induction | 1 | 1999 | 88 | 0.040 |
Why?
|
Epidermal Growth Factor | 1 | 2000 | 119 | 0.040 |
Why?
|
Second Messenger Systems | 1 | 1999 | 41 | 0.040 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2000 | 136 | 0.040 |
Why?
|
Collagen Type I | 1 | 2019 | 62 | 0.040 |
Why?
|
Hepatitis C | 1 | 2001 | 208 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2004 | 746 | 0.040 |
Why?
|
Heart Rate | 4 | 2007 | 492 | 0.040 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 1998 | 153 | 0.040 |
Why?
|
Inositol Phosphates | 1 | 1998 | 16 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 1998 | 74 | 0.040 |
Why?
|
COS Cells | 1 | 1998 | 166 | 0.040 |
Why?
|
Gene Targeting | 1 | 1998 | 72 | 0.040 |
Why?
|
Adenylate Cyclase Toxin | 1 | 1997 | 14 | 0.040 |
Why?
|
Sarcolemma | 1 | 1997 | 30 | 0.040 |
Why?
|
Tachycardia | 1 | 1997 | 35 | 0.040 |
Why?
|
United States | 3 | 2016 | 6672 | 0.040 |
Why?
|
Cardiac Catheterization | 1 | 1999 | 291 | 0.040 |
Why?
|
Myocardial Ischemia | 1 | 1998 | 162 | 0.040 |
Why?
|
Propensity Score | 1 | 2017 | 136 | 0.040 |
Why?
|
Genetic Therapy | 1 | 1999 | 342 | 0.040 |
Why?
|
Coronary Artery Bypass, Off-Pump | 1 | 2017 | 35 | 0.040 |
Why?
|
Protein Isoforms | 2 | 2010 | 270 | 0.040 |
Why?
|
Organ Size | 1 | 2017 | 364 | 0.040 |
Why?
|
Adaptation, Physiological | 1 | 1999 | 306 | 0.040 |
Why?
|
Calcium | 3 | 2010 | 1156 | 0.040 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2017 | 134 | 0.030 |
Why?
|
Random Allocation | 2 | 2007 | 332 | 0.030 |
Why?
|
Cost Savings | 1 | 2016 | 66 | 0.030 |
Why?
|
B-Lymphocytes | 1 | 2000 | 724 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2013 | 1686 | 0.030 |
Why?
|
Epithelial Cells | 1 | 2000 | 669 | 0.030 |
Why?
|
India | 1 | 2016 | 120 | 0.030 |
Why?
|
G-Protein-Coupled Receptor Kinase 5 | 3 | 2001 | 4 | 0.030 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2016 | 166 | 0.030 |
Why?
|
Intestinal Mucosa | 1 | 2000 | 797 | 0.030 |
Why?
|
Cold Ischemia | 1 | 2014 | 17 | 0.030 |
Why?
|
Metabolic Clearance Rate | 1 | 2014 | 121 | 0.030 |
Why?
|
Hemodynamics | 3 | 2005 | 710 | 0.030 |
Why?
|
Warm Ischemia | 1 | 2014 | 28 | 0.030 |
Why?
|
Echocardiography, Transesophageal | 1 | 2016 | 344 | 0.030 |
Why?
|
Prospective Studies | 2 | 2014 | 4213 | 0.030 |
Why?
|
Connexin 43 | 1 | 2014 | 94 | 0.030 |
Why?
|
Lung Diseases | 1 | 2016 | 263 | 0.030 |
Why?
|
Gap Junctions | 1 | 2014 | 142 | 0.030 |
Why?
|
Cadherins | 1 | 2014 | 151 | 0.030 |
Why?
|
Bangladesh | 1 | 2014 | 318 | 0.030 |
Why?
|
Lung | 1 | 1999 | 1170 | 0.030 |
Why?
|
Postoperative Period | 1 | 2014 | 303 | 0.030 |
Why?
|
Dobutamine | 1 | 2012 | 61 | 0.030 |
Why?
|
Antigens, CD | 1 | 2014 | 458 | 0.030 |
Why?
|
Databases as Topic | 1 | 2012 | 92 | 0.030 |
Why?
|
Models, Economic | 1 | 2012 | 60 | 0.030 |
Why?
|
Fatal Outcome | 2 | 2004 | 293 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2014 | 1204 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2012 | 364 | 0.020 |
Why?
|
Comorbidity | 1 | 2015 | 943 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2014 | 937 | 0.020 |
Why?
|
Dopamine | 1 | 2012 | 275 | 0.020 |
Why?
|
Hepatitis A Virus Cellular Receptor 1 | 1 | 2010 | 19 | 0.020 |
Why?
|
Lipocalin-2 | 1 | 2010 | 38 | 0.020 |
Why?
|
Lipocalins | 1 | 2010 | 35 | 0.020 |
Why?
|
Prevalence | 1 | 2014 | 1239 | 0.020 |
Why?
|
Cystatin C | 1 | 2010 | 31 | 0.020 |
Why?
|
Acute-Phase Proteins | 1 | 2010 | 37 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2014 | 819 | 0.020 |
Why?
|
Receptors, Virus | 1 | 2010 | 74 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 1621 | 0.020 |
Why?
|
Glutathione Transferase | 1 | 2010 | 111 | 0.020 |
Why?
|
Green Fluorescent Proteins | 2 | 2001 | 305 | 0.020 |
Why?
|
Cricetulus | 2 | 2000 | 126 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2012 | 689 | 0.020 |
Why?
|
Isomerism | 1 | 2010 | 28 | 0.020 |
Why?
|
Age Factors | 1 | 2015 | 1851 | 0.020 |
Why?
|
Hepatocyte Growth Factor | 1 | 2010 | 84 | 0.020 |
Why?
|
Myofibrils | 1 | 2010 | 23 | 0.020 |
Why?
|
Odds Ratio | 1 | 2012 | 678 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2010 | 131 | 0.020 |
Why?
|
Dimerization | 1 | 2010 | 143 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2012 | 349 | 0.020 |
Why?
|
Cricetinae | 2 | 2000 | 560 | 0.020 |
Why?
|
Patient Discharge | 1 | 2012 | 300 | 0.020 |
Why?
|
Reference Values | 2 | 2001 | 674 | 0.020 |
Why?
|
Temperature | 1 | 2010 | 396 | 0.020 |
Why?
|
Actin Cytoskeleton | 1 | 2010 | 192 | 0.020 |
Why?
|
Homeostasis | 1 | 2010 | 409 | 0.020 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 1075 | 0.020 |
Why?
|
I-kappa B Proteins | 1 | 2007 | 53 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2014 | 806 | 0.020 |
Why?
|
Amino Acid Motifs | 1 | 2005 | 116 | 0.020 |
Why?
|
Calmodulin | 1 | 2005 | 50 | 0.020 |
Why?
|
Systole | 1 | 2005 | 129 | 0.020 |
Why?
|
Diastole | 1 | 2005 | 144 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2005 | 290 | 0.020 |
Why?
|
Caveolin 3 | 1 | 2004 | 4 | 0.020 |
Why?
|
Benzophenanthridines | 1 | 2004 | 23 | 0.020 |
Why?
|
Phenanthridines | 1 | 2004 | 24 | 0.020 |
Why?
|
Stimulation, Chemical | 1 | 2004 | 63 | 0.020 |
Why?
|
Staurosporine | 1 | 2004 | 33 | 0.020 |
Why?
|
Alkaloids | 1 | 2004 | 45 | 0.020 |
Why?
|
Chest Tubes | 1 | 2004 | 23 | 0.020 |
Why?
|
Candidiasis | 1 | 2004 | 36 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 1999 | 1753 | 0.020 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2004 | 121 | 0.020 |
Why?
|
Thoracic Surgical Procedures | 1 | 2004 | 44 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 1 | 2004 | 143 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2005 | 736 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2016 | 2262 | 0.010 |
Why?
|
Syndrome | 1 | 2004 | 446 | 0.010 |
Why?
|
NF-kappa B | 1 | 2007 | 444 | 0.010 |
Why?
|
Prognosis | 1 | 2010 | 3679 | 0.010 |
Why?
|
Feces | 1 | 2004 | 319 | 0.010 |
Why?
|
Adolescent | 1 | 2014 | 8981 | 0.010 |
Why?
|
Cell Membrane Permeability | 1 | 2001 | 119 | 0.010 |
Why?
|
Receptors, IgE | 1 | 2000 | 7 | 0.010 |
Why?
|
CD5 Antigens | 1 | 2000 | 14 | 0.010 |
Why?
|
Antigens, CD20 | 1 | 2000 | 36 | 0.010 |
Why?
|
Action Potentials | 1 | 2004 | 573 | 0.010 |
Why?
|
Antigens, CD19 | 1 | 2000 | 39 | 0.010 |
Why?
|
Biotin | 1 | 1999 | 44 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2001 | 1041 | 0.010 |
Why?
|
Rats, Inbred LEC | 1 | 1999 | 1 | 0.010 |
Why?
|
Monocrotaline | 1 | 1999 | 12 | 0.010 |
Why?
|
Bone Marrow Cells | 1 | 2000 | 253 | 0.010 |
Why?
|
Colforsin | 1 | 1999 | 74 | 0.010 |
Why?
|
Ethanolamines | 1 | 1999 | 32 | 0.010 |
Why?
|
Pulmonary Circulation | 1 | 1999 | 86 | 0.010 |
Why?
|
Biological Transport | 1 | 1999 | 396 | 0.010 |
Why?
|
Thionucleotides | 1 | 1999 | 56 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2000 | 679 | 0.010 |
Why?
|
Norepinephrine | 1 | 1999 | 167 | 0.010 |
Why?
|
Models, Biological | 1 | 2005 | 1749 | 0.010 |
Why?
|
Transplantation, Heterotopic | 1 | 1998 | 45 | 0.010 |
Why?
|
Graft Rejection | 1 | 2004 | 1065 | 0.010 |
Why?
|
Lac Operon | 1 | 1998 | 46 | 0.010 |
Why?
|
beta-Galactosidase | 1 | 1998 | 71 | 0.010 |
Why?
|
Dogs | 1 | 1999 | 685 | 0.010 |
Why?
|
Blotting, Western | 1 | 1999 | 782 | 0.010 |
Why?
|
Rats, Inbred Strains | 1 | 1998 | 312 | 0.010 |
Why?
|
Luciferases | 1 | 1998 | 118 | 0.010 |
Why?
|
Imidazoles | 1 | 1999 | 162 | 0.010 |
Why?
|
Myosin Heavy Chains | 1 | 1998 | 88 | 0.010 |
Why?
|
Calcium Channels | 1 | 1999 | 182 | 0.010 |
Why?
|
Cattle | 1 | 1998 | 376 | 0.010 |
Why?
|
Receptors, Angiotensin | 1 | 1996 | 15 | 0.010 |
Why?
|
Phenotype | 1 | 1996 | 2378 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2000 | 2360 | 0.010 |
Why?
|